Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 30
Semaglutide lowers hsCRP in SELECT
A Circulation analysis of SELECT finds semaglutide 2.4 mg reduces hsCRP in adults with prior heart attack or stroke. What it means, and what it doesn't.
Sleep and mood after starting GLP-1 drugs
A new observational study links tirzepatide and semaglutide to improved sleep and depression scores at three months, with caveats.
Doctor suspended over Ozempic to partner
A GMC tribunal suspended a UK doctor for prescribing Ozempic and Wegovy, both semaglutide, to her partner without disclosure.
Experts Issue GLP-1 Guidance for NET Care
A new expert consensus statement sets ground rules for using GLP-1 drugs like tirzepatide in neuroendocrine tumor patients.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.
Semaglutide Plus Luseogliflozin for MASH
A small randomised trial tested adding the SGLT2 drug luseogliflozin to semaglutide for MASH. Here is what the numbers did and did not show.
Ozempic in Pro-Eating-Disorder Communities
A 2026 study finds Ozempic, a semaglutide brand, is normalized more than warned against in a pro-eating-disorder community on X.
Semaglutide and aspiration risk in surgery
New ultrasound data and case reports on semaglutide, retained gastric content and aspiration are reshaping the pre-surgery cessation question.
Tesamorelin and ipamorelin: side effects
Racing heart, flushing, and dizziness after combining tesamorelin and ipamorelin with TRT: what the evidence says and when to seek care.
Thymosin β4 curbs colitis in mouse study
A 2026 mouse study found thymosin beta-4, the peptide sold as TB-500, eased colitis and gut fibrosis through a newly proposed receptor pathway.
CJC-1295 and Ipamorelin, Explained
CJC-1295 and ipamorelin are unapproved growth-hormone-axis peptides. Here is what the evidence shows, and why we will not give you a starting dose.
CJC-1295 in sports medicine: the evidence
A 2026 UCLA scoping review found that CJC-1295's claimed benefits for musculoskeletal recovery and athletic performance remain unsubstantiated by human trials.